FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:462-467 August 15, 1996 Number 7 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

ABSTRACT

Background Uncontrolled studies suggest that a combination of chemotherapy and radiotherapy improves the survival of patients with esophageal adenocarcinoma. We conducted a prospective, randomized trial comparing surgery alone with combined chemotherapy, radiotherapy, and surgery.

Methods Patients assigned to multimodal therapy received two courses of chemotherapy in weeks 1 and 6 (fluorouracil, 15 mg per kilogram of body weight daily for five days, and cisplatin, 75 mg per square meter of body-surface area on day 7) and a course of radiotherapy (40 Gy, administered in 15 fractions over a three-week period, beginning concurrently with the first course of chemotherapy), followed by surgery. The patients assigned to surgery had no preoperative therapy.

Results Of the 58 patients assigned to multimodal therapy and the 55 assigned to surgery, 10 and 1, respectively, were withdrawn for protocol violations. At the time of surgery, 23 of 55 patients (42 percent) treated with preoperative multimodal therapy who could be evaluated had positive nodes or metastases, as compared with 45 of the 55 patients (82 percent) who underwent surgery alone (P<0.001). Thirteen of the 52 patients (25 percent) who underwent surgery after multimodal therapy had complete responses, as determined pathologically. The median survival of patients assigned to multimodal therapy was 16 months, as compared with 11 months for those assigned to surgery alone (P = 0.01). At one, two, and three years, 52, 37, and 32 percent, respectively, of patients assigned to multimodal therapy were alive, as compared with 44, 26, and 6 percent of those assigned to surgery, with the survival advantage favoring multimodal therapy reaching significance at three years (P = 0.01).

Conclusions Multimodal treatment is superior to surgery alone for patients with resectable adenocarcinoma of the esophagus.

Source Information

From the Departments of Surgery (T.N.W., T.P.J.H.) and Gastroenterology (N.N., N.K.), St. James's Hospital; the Department of Radiotherapy, St. Luke's Hospital (D.H.); and the Departments of Community Health and Statistics, Trinity College (A.K.) — all in Dublin, Ireland.

Address reprint requests to Dr. Walsh at the Department of Surgery, Beaumont Hospital, Dublin 9, Ireland.

Full Text of this Article

Related Letters:

Multimodal Therapy for Esophageal Adenocarcinoma
Badwe R. A., Vaidya J. S., Bhansali M. S., Gaffney P., Funk E. M., Witte J., Walsh T. N., Kelly A., Hennessy T. P.J.
Extract | Full Text  
N Engl J Med 1997; 336:374-376, Jan 30, 1997. Correspondence

This article has been cited by other articles:

• Bollschweiler, E., Metzger, R., Drebber, U., Baldus, S., Vallbohmer, D., Kocher, M., Holscher, A. H. (2008). Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol 0: mdn622v1-mdn622 [Abstract] [Full Text]  
• Higuchi, I., Yasuda, T., Yano, M., Doki, Y., Miyata, H., Tatsumi, M., Fukunaga, H., Takiguchi, S., Fujiwara, Y., Hatazawa, J., Monden, M. (2008). Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma. J. Thorac. Cardiovasc. Surg. 136: 205-212 [Abstract] [Full Text]  
• Kim, M. K., Cho, K.-J., Kwon, G. Y., Park, S.-I., Kim, Y. H., Kim, J. H., Song, H.-Y., Shin, J. H., Jung, H. Y., Lee, G. H., Choi, K. D., Kim, S.-B. (2008). Patients with ERCC1-Negative Locally Advanced Esophageal Cancers May Benefit from Preoperative Chemoradiotherapy. Clin. Cancer Res. 14: 4225-4231 [Abstract] [Full Text]  
• Wilkinson, N. W., Howe, J., Gay, G., Patel-Parekh, L., Scott-Conner, C., Donohue, J. (2008). Differences in the Pattern of Presentation and Treatment of Proximal and Distal Gastric Cancer: Results of the 2001 Gastric Patient Care Evaluation. Ann. Surg. Oncol. 15: 1644-1650 [Abstract] [Full Text]  
• Pennathur, A., Luketich, J. D., Landreneau, R. J., Ward, J., Christie, N. A., Gibson, M. K., Schuchert, M., Cooper, K., Land, S. R., Belani, C. P. (2008). Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.. Ann. Thorac. Surg. 85: 1930-1936 [Abstract] [Full Text]  
• Rizzetto, C., DeMeester, S.R., Hagen, J.A., Peyre, C.G., Lipham, J.C., DeMeester, T.R. (2008). En bloc esophagectomy reduces local recurrence and improves survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma.. J. Thorac. Cardiovasc. Surg. 135: 1228-1236 [Abstract] [Full Text]  
• Tepper, J., Krasna, M. J., Niedzwiecki, D., Hollis, D., Reed, C. E., Goldberg, R., Kiel, K., Willett, C., Sugarbaker, D., Mayer, R. (2008). Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781. JCO 26: 1086-1092 [Abstract] [Full Text]  
• Pennathur, A., Luketich, J. D. (2008). Resection for Esophageal Cancer: Strategies for Optimal Management. Ann. Thorac. Surg. 85: S751-S756 [Abstract] [Full Text]  
• Wouters, M. W., Wijnhoven, B. P., Karim-Kos, H. E., Blaauwgeers, H. G., Stassen, L. P., Steup, W.-H., W.Tilanus, H., Tollenaar, R. A. (2008). High-Volume versus Low-Volume for Esophageal Resections for Cancer: The Essential Role of Case-Mix Adjustments based on Clinical Data. Ann. Surg. Oncol. 15: 80-87 [Abstract] [Full Text]  
• van de Schoot, L., Romme, E. A. P. M., van der Sangen, M. J., Creemers, G. J., van Lijnschoten, G., Repelaer van Driel, O. J., Rutten, H. J. T., Nieuwenhuijzen, G. A. P. (2008). A Highly Active and Tolerable Neoadjuvant Regimen Combining Paclitaxel, Carboplatin, 5-FU, and Radiation Therapy in Patients with Stage II and III Esophageal Cancer. Ann. Surg. Oncol. 15: 88-95 [Abstract] [Full Text]  
• Ilson, D. H. (2008). Combined Modality Therapy for Gastric, Esophageal, and Gastroesophageal Junction Cancers. Am Soc Clin Oncol Ed Book 2008: 177-182 [Abstract] [Full Text]  
• Krasna, M. J. (2008). Stage-specific Therapy for Esophageal Cancer: The Role of Multimodality Therapy. Am Soc Clin Oncol Ed Book 2008: e19-e22 [Abstract] [Full Text]  
• Faried, A., Faried, L. S., Usman, N., Kato, H., Kuwano, H. (2007). Clinical and Prognostic Significance of RhoA and RhoC Gene Expression in Esophageal Squamous Cell Carcinoma. Ann. Surg. Oncol. 14: 3593-3601 [Abstract] [Full Text]  
• Healy, L. A., Ryan, A. M., Gopinath, B., Rowley, S., Byrne, P. J., Reynolds, J. V. (2007). Impact of obesity on outcomes in the management of localized adenocarcinoma of the esophagus and esophagogastric junction.. J. Thorac. Cardiovasc. Surg. 134: 1284-1291 [Abstract] [Full Text]  
• Ruol, A., Portale, G., Castoro, C., Merigliano, S., Cagol, M., Cavallin, F., Sileni, V. C., Corti, L., Rampado, S., Costantini, M., Ancona, E. (2007). Effects of Neoadjuvant Therapy on Perioperative Morbidity in Elderly Patients Undergoing Esophagectomy for Esophageal Cancer. Ann. Surg. Oncol. 14: 3243-3250 [Abstract] [Full Text]  
• Bruzzi, J. F., Munden, R. F., Truong, M. T., Marom, E. M., Sabloff, B. S., Gladish, G. W., Iyer, R. B., Pan, T.-S., Macapinlac, H. A., Erasmus, J. J. (2007). PET/CT of Esophageal Cancer: Its Role in Clinical Management. RadioGraphics 27: 1635-1652 [Abstract] [Full Text]  
• MacGuill, M. J, Barrett, C., Ravi, N., MacDonald, G., Reynolds, J. V (2007). Isolated tumour cells in pathological node-negative lymph nodes adversely affect prognosis in cancer of the oesophagus or oesophagogastric junction. J. Clin. Pathol. 60: 1108-1111 [Abstract] [Full Text]  
• Kleinberg, L., Forastiere, A. A. (2007). Chemoradiation in the Management of Esophageal Cancer. JCO 25: 4110-4117 [Abstract] [Full Text]  
• Gotoh, M., Takiuchi, H., Kawabe, S.-i., Ohta, S., Kii, T., Kuwakado, S., Katsu, K.-i. (2007). Epidermal Growth Factor Receptor is a Possible Predictor of Sensitivity to Chemoradiotherapy in the Primary Lesion of Esophageal Squamous Cell Carcinoma. Jpn J Clin Oncol 37: 652-657 [Abstract] [Full Text]  
• Ardalan, B., Spector, S. A., Livingstone, A. S., Franceschi, D., Mezentsev, D., Lima, M., Bowen-Wells, C. P., Sparling, L., Avisar, E., Sapp, M., Rios, J., Walker, G., Ganjei-Azar, P. (2007). Neoadjuvant, Surgery and Adjuvant Chemotherapy without Radiation for Esophageal Cancer. Jpn J Clin Oncol 0: hym076v1-7 [Abstract] [Full Text]  
• Bedenne, L., Michel, P., Bouche, O., Milan, C., Mariette, C., Conroy, T., Pezet, D., Roullet, B., Seitz, J.-F., Herr, J.-P., Paillot, B., Arveux, P., Bonnetain, F., Binquet, C. (2007). Chemoradiation Followed by Surgery Compared With Chemoradiation Alone in Squamous Cancer of the Esophagus: FFCD 9102. JCO 25: 1160-1168 [Abstract] [Full Text]  
• Onate-Ocana, L. F., Milan-Revollo, G., Aiello-Crocifoglio, V., Carrillo, J. F., Gallardo-Rincon, D., Brom-Valladares, R., Herrera-Goepfert, R., Duenas-Gonzalez, A. (2007). Treatment of the Adenocarcinoma of the Esophagogastric Junction at a Single Institution in Mexico. Ann. Surg. Oncol. 14: 1439-1448 [Abstract] [Full Text]  
• Graham, A. J., Shrive, F. M., Ghali, W. A., Manns, B. J., Grondin, S. C., Finley, R. J., Clifton, J. (2007). Defining the Optimal Treatment of Locally Advanced Esophageal Cancer: A Systematic Review and Decision Analysis. Ann. Thorac. Surg. 83: 1257-1264 [Abstract] [Full Text]  
• Kim, T. J., Lee, K. H., Kim, Y. H., Sung, S. W., Jheon, S., Cho, S.-k., Lee, K. W. (2007). Postoperative Imaging of Esophageal Cancer: What Chest Radiologists Need to Know. RadioGraphics 27: 409-429 [Abstract] [Full Text]  
• Rizk, N. P., Venkatraman, E., Bains, M. S., Park, B., Flores, R., Tang, L., Ilson, D. H., Minsky, B. D., Rusch, V. W. (2007). American Joint Committee on Cancer Staging System Does Not Accurately Predict Survival in Patients Receiving Multimodality Therapy for Esophageal Adenocarcinoma. JCO 25: 507-512 [Abstract] [Full Text]  
• Barbour, A. P., Rizk, N. P., Gonen, M., Tang, L., Bains, M. S., Rusch, V. W., Coit, D. G., Brennan, M. F. (2007). Lymphadenectomy for Adenocarcinoma of the Gastroesophageal Junction (GEJ): Impact of Adequate Staging on Outcome. Ann. Surg. Oncol. 14: 306-316 [Abstract] [Full Text]  
• Prenzel, K. L., Konig, A., Schneider, P. M., Schnickmann, C., Baldus, S. E., Schroder, W., Bollschweiler, E., Dienes, H. P., Mueller, R. P., Izbicki, J. R., Holscher, A. H. (2007). Reduced Incidence of Nodal Micrometastasis after Major Response to Neoadjuvant Chemoradiation in Locally Advanced Esophageal Cancer. Ann. Surg. Oncol. 14: 954-959 [Abstract] [Full Text]  
• Gee, D. W., Rattner, D. W. (2007). Management of Gastroesophageal Tumors. The Oncologist 12: 175-185 [Abstract] [Full Text]  
• Lin, C-C, Hsu, C-H, Cheng, J., Wang, H-P, Lee, J-M, Yeh, K-H, Yang, C-H, Lin, J-T, Cheng, A-L, Lee, Y-C (2007). Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 18: 93-98 [Abstract] [Full Text]  
• Lagarde, S. M., ten Kate, F. J.W., Reitsma, J. B., Busch, O. R.C., van Lanschot, J. J. B. (2006). Prognostic Factors in Adenocarcinoma of the Esophagus or Gastroesophageal Junction. JCO 24: 4347-4355 [Abstract] [Full Text]  
• Reynolds, J. V., Ravi, N., Hollywood, D., Kennedy, M. J., Rowley, S., Ryan, A., Hughes, N., Carey, M., Byrne, P. (2006). Neoadjuvant chemoradiation may increase the risk of respiratory complications and sepsis after transthoracic esophagectomy. J. Thorac. Cardiovasc. Surg. 132: 549-555 [Abstract] [Full Text]  
• Bai, J.-G., Lv, Y., Dang, C.-X. (2006). Adenocarcinoma of the Esophagogastric Junction in China According to Siewert's Classification. Jpn J Clin Oncol 36: 364-367 [Abstract] [Full Text]  
• Mariette, C., Triboulet, J.-P. (2006). Should Resectable Esophageal Cancer Be Resected?. Ann. Surg. Oncol. 13: 447-449 [Full Text]  
• Gaca, J. G., Petersen, R. P., Peterson, B. L., Harpole, D. H. Jr., D'Amico, T. A., Pappas, T. N., Seigler, H. F., Wolfe, W. G., Tyler, D. S. (2006). Pathologic Nodal Status Predicts Disease-Free Survival After Neoadjuvant Chemoradiation for Gastroesophageal Junction Carcinoma. Ann. Surg. Oncol. 13: 340-346 [Abstract] [Full Text]  
• Henry, L. R., Goldberg, M., Scott, W., Konski, A., Meropol, N. J., Freedman, G., Weiner, L. M., Watts, P., Beard, M., McLaughlin, S., Cheng, J. D. (2006). Induction Cisplatin and Paclitaxel Followed by Combination Chemoradiotherapy with 5-Fluorouracil, Cisplatin, and Paclitaxel Before Resection in Localized Esophageal Cancer: A Phase II Report. Ann. Surg. Oncol. 13: 214-220 [Abstract] [Full Text]  
• DeMeester, S. R. (2006). Adenocarcinoma of the Esophagus and Cardia: A Review of the Disease and Its Treatment. Ann. Surg. Oncol. 13: 12-30 [Abstract] [Full Text]  
• Xi, H., Baldus, S. E., Warnecke-Eberz, U., Brabender, J., Neiss, S., Metzger, R., Ling, F. C., Dienes, H. P., Bollschweiler, E., Moenig, S., Mueller, R. P., Hoelscher, A. H., Schneider, P. M. (2005). High Cyclooxygenase-2 Expression Following Neoadjuvant Radiochemotherapy Is Associated with Minor Histopathologic Response and Poor Prognosis in Esophageal Cancer. Clin. Cancer Res. 11: 8341-8347 [Abstract] [Full Text]  
• Hayashida, Y., Honda, K., Osaka, Y., Hara, T., Umaki, T., Tsuchida, A., Aoki, T., Hirohashi, S., Yamada, T. (2005). Possible Prediction of Chemoradiosensitivity of Esophageal Cancer by Serum Protein Profiling. Clin. Cancer Res. 11: 8042-8047 [Abstract] [Full Text]  
• Barclay, C., Li, A. W., Geldenhuys, L., Baguma-Nibasheka, M., Porter, G. A., Veugelers, P. J., Murphy, P. R., Casson, A. G. (2005). Basic Fibroblast Growth Factor (FGF-2) Overexpression Is a Risk Factor for Esophageal Cancer Recurrence and Reduced Survival, which Is Ameliorated by Coexpression of the FGF-2 Antisense Gene. Clin. Cancer Res. 11: 7683-7691 [Abstract] [Full Text]  
• Lee, J., Lee, K.-E., Im, Y.-H., Kang, W. K., Park, K., Kim, K., Shim, Y. M. (2005). Adjuvant Chemotherapy with 5-Fluorouracil and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma. Ann. Thorac. Surg. 80: 1170-1175 [Abstract] [Full Text]  
• de Manzoni, G., Pedrazzani, C., Laterza, E., Pasini, F., Grandinetti, A., Bernini, M., Ruzzenente, A., Zerman, G., Tomezzoli, A., Cordiano, C. (2005). Induction Chemoradiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus: Impact of Increased Dosage on Long-Term Results. Ann. Thorac. Surg. 80: 1176-1183 [Abstract] [Full Text]  
• Tew, W. P., Kelsen, D. P., Ilson, D. H. (2005). Targeted Therapies for Esophageal Cancer. The Oncologist 10: 590-601 [Abstract] [Full Text]  
• Abou-Jawde, R. M., Mekhail, T., Adelstein, D. J., Rybicki, L. A., Mazzone, P. J., Caroll, M. A., Rice, T. W. (2005). Impact of Induction Concurrent Chemoradiotherapy on Pulmonary Function and Postoperative Acute Respiratory Complications in Esophageal Cancer. Chest 128: 250-255 [Abstract] [Full Text]  
• Berger, A. C., Farma, J., Scott, W. J., Freedman, G., Weiner, L., Cheng, J. D., Wang, H., Goldberg, M. (2005). Complete Response to Neoadjuvant Chemoradiotherapy in Esophageal Carcinoma Is Associated With Significantly Improved Survival. JCO 23: 4330-4337 [Abstract] [Full Text]  
• Pasini, F., de Manzoni, G., Pedrazzani, C., Grandinetti, A., Durante, E., Gabbani, M., Tomezzoli, A., Griso, C., Guglielmi, A., Pelosi, G., Maluta, S., Cetto, G. L., Cordiano, C. (2005). High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy. Ann Oncol 16: 1133-1139 [Abstract] [Full Text]  
• Lee, J.-M., Wu, M.-T., Lee, Y.-C., Yang, S.-Y., Chen, J.-S., Hsu, H.-H., Huang, P.-M., Kuo, S.-W., Lee, C.-J., Chen, C.-J. (2005). Association of GSTP1 Polymorphism and Survival for Esophageal Cancer. Clin. Cancer Res. 11: 4749-4753 [Abstract] [Full Text]  
• Cerfolio, R. J., Bryant, A. S., Ohja, B., Bartolucci, A. A., Eloubeidi, M. A. (2005). The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J. Thorac. Cardiovasc. Surg. 129: 1232-1241 [Abstract] [Full Text]  
• Agarwal, B., Swisher, S. G., Ajani, J., Kelly, K., Komaki, R. R., Abu-Hamda, E., Correa, A. M., Roth, J. A. (2005). Differential Response to Preoperative Chemoradiation and Surgery in Esophageal Adenocarcinomas Based on Presence of Barrett's Esophagus and Symptomatic Gastroesophageal Reflux. Ann. Thorac. Surg. 79: 1716-1723 [Abstract] [Full Text]  
• Suntharalingam, M., Moughan, J., Coia, L. R., Krasna, M. J., Kachnic, L., Haller, D. G., Willet, C. G., John, M. J., Minsky, B. D., Owen, J. B. (2005). Outcome Results of the 1996-1999 Patterns of Care Survey of the National Practice for Patients Receiving Radiation Therapy for Carcinoma of the Esophagus. JCO 23: 2325-2331 [Abstract] [Full Text]  
• Moore Joshi, M.-B., Shirota, Y., Danenberg, K. D., Conlon, D. H., Salonga, D. S., Herndon, J. E. II, Danenberg, P. V., Harpole, D. H. Jr. (2005). High Gene Expression of TS1, GSTP1, and ERCC1 Are Risk Factors for Survival in Patients Treated with Trimodality Therapy for Esophageal Cancer. Clin. Cancer Res. 11: 2215-2221 [Abstract] [Full Text]  
• DeMeester, S R (2005). Reoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 54: 440-441 [Full Text]  
• Rice, D. C., Correa, A. M., Vaporciyan, A. A., Sodhi, N., Smythe, W. R., Swisher, S. G., Walsh, G. L., Putnam, J. B. Jr, Komaki, R., Ajani, J. A., Roth, J. A. (2005). Preoperative Chemoradiotherapy Prior to Esophagectomy in Elderly Patients is Not Associated With Increased Morbidity. Ann. Thorac. Surg. 79: 391-397 [Abstract] [Full Text]  
• Armanios, M., Xu, R., Forastiere, A. A., Haller, D. G., Kugler, J. W., Benson, A. B. III (2004). Adjuvant Chemotherapy for Resected Adenocarcinoma of the Esophagus, Gastro-Esophageal Junction, and Cardia: Phase II Trial (E8296) of the Eastern Cooperative Oncology Group. JCO 22: 4495-4499 [Abstract] [Full Text]  
• Lin, F. C.-F., Durkin, A. E., Ferguson, M. K. (2004). Induction Therapy Does Not Increase Surgical Morbidity After Esophagectomy for Cancer. Ann. Thorac. Surg. 78: 1783-1789 [Abstract] [Full Text]  
• Swisher, S. G., Maish, M., Erasmus, J. J., Correa, A. M., Ajani, J. A., Bresalier, R., Komaki, R., Macapinlac, H., Munden, R. F., Putnam, J. B., Rice, D., Smythe, W. R., Vaporciyan, A. A., Walsh, G. L., Wu, T. T., Roth, J. A. (2004). Utility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal Cancer. Ann. Thorac. Surg. 78: 1152-1160 [Abstract] [Full Text]  
• Fiorica, F, Di Bona, D, Schepis, F, Licata, A, Shahied, L, Venturi, A, Falchi, A M, Craxi, A, Camma, C (2004). Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 53: 925-930 [Abstract] [Full Text]  
• Iyer, R., Wilkinson, N., Demmy, T., Javle, M. (2004). Controversies in the Multimodality Management of Locally Advanced Esophageal Cancer: Evidence-Based Review of Surgery Alone and Combined-Modality Therapy. Ann. Surg. Oncol. 11: 665-673 [Abstract] [Full Text]  
• Lee, J.-L., Park, S. I., Kim, S.-B., Jung, H.-Y., Lee, G. H., Kim, J.-H., Song, H.-Y., Cho, K.-J., Kim, W.-K., Lee, J.-S., Kim, S.-H., Min, Y.-I. (2004). A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 15: 947-954 [Abstract] [Full Text]  
• Johansson, J., DeMeester, T. R., Hagen, J. A., DeMeester, S. R., Peters, J. H., Oberg, S., Bremner, C. G. (2004). En Bloc vs Transhiatal Esophagectomy for Stage T3 N1 Adenocarcinoma of the Distal Esophagus. Arch Surg 139: 627-633 [Abstract] [Full Text]  
• Warnecke-Eberz, U., Metzger, R., Miyazono, F., Baldus, S. E., Neiss, S., Brabender, J., Schaefer, H., Doerfler, W., Bollschweiler, E., Dienes, H. P., Mueller, R. P., Danenberg, P. V., Hoelscher, A. H., Schneider, P. M. (2004). High Specificity of Quantitative Excision Repair Cross-Complementing 1 Messenger RNA Expression for Prediction of Minor Histopathological Response to Neoadjuvant Radiochemotherapy in Esophageal Cancer. Clin. Cancer Res. 10: 3794-3799 [Abstract] [Full Text]  
• Malaisrie, S. C., Untch, B., Aranha, G. V., Mohideen, N., Hantel, A., Pickleman, J. (2004). Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Cancer: Experience at a Single Institution. Arch Surg 139: 532-539 [Abstract] [Full Text]  
• Koshy, M., Esiashvilli, N., Landry, J. C., Thomas, C. R. Jr., Matthews, R. H. (2004). Multiple Management Modalities in Esophageal Cancer: Combined Modality Management Approaches. The Oncologist 9: 147-159 [Abstract] [Full Text]  
• Mackenzie, D. J., Popplewell, P. K., Billingsley, K. G. (2004). Care of Patients After Esophagectomy. Crit Care Nurse 24: 16-29 [Full Text]  
• Gibson, M. K., Abraham, S. C., Wu, T.-T., Burtness, B., Heitmiller, R. F., Heath, E., Forastiere, A. (2003). Epidermal Growth Factor Receptor, p53 Mutation, and Pathological Response Predict Survival in Patients with Locally Advanced Esophageal Cancer Treated with Preoperative Chemoradiotherapy. Clin. Cancer Res. 9: 6461-6468 [Abstract] [Full Text]  
• Enzinger, P. C., Mayer, R. J. (2003). Esophageal Cancer. NEJM 349: 2241-2252 [Full Text]  
• Rice, T. W., Adelstein, D. J., Chidel, M. A., Rybicki, L. A., DeCamp, M. M., Murthy, S. C., Blackstone, E. H. (2003). Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma. J. Thorac. Cardiovasc. Surg. 126: 1590-1596 [Abstract] [Full Text]  
• Keresztes, R. S., Port, J. L., Pasmantier, M. W., Korst, R. J., Altorki, N. K. (2003). Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: Results of a phase II trial. J. Thorac. Cardiovasc. Surg. 126: 1603-1608 [Abstract] [Full Text]  
• Darnton, S.J., Archer, V.R., Stocken, D.D., Mulholland, P.J., Casson, A.G., Ferry, D.R. (2003). Preoperative Mitomycin, Ifosfamide, and Cisplatin Followed by Esophagectomy in Squamous Cell Carcinoma of the Esophagus: Pathologic Complete Response Induced by Chemotherapy Leads to Long-Term Survival. JCO 21: 4009-4015 [Abstract] [Full Text]  
• Rasanen, J. V., Sihvo, E. I. T., Knuuti, M. J., Minn, H. R. I., Luostarinen, M. E. S., Laippala, P., Viljanen, T., Salo, J. A. (2003). Prospective Analysis of Accuracy of Positron Emission Tomography, Computed Tomography, and Endoscopic Ultrasonography in Staging of Adenocarcinoma of the Esophagus and the Esophagogastric Junction. Ann. Surg. Oncol. 10: 954-960 [Abstract] [Full Text]  
• Goldberg, M., Farma, J., Lampert, C., Colarusso, P., Coia, L., Frucht, H., Goosenberg, E., Beard, M., Weiner, L. M. (2003). Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: A phase I report. J. Thorac. Cardiovasc. Surg. 126: 1168-1173 [Abstract] [Full Text]  
• Drovdlic, C M, Goddard, K A B, Chak, A, Brock, W, Chessler, L, King, J F, Richter, J, Falk, G W, Johnston, D K, Fisher, J L, Grady, W M, Lemeshow, S, Eng, C (2003). Demographic and phenotypic features of 70 families segregating Barrett's oesophagus and oesophageal adenocarcinoma. J. Med. Genet. 40: 651-656 [Abstract] [Full Text]  
• Hagry, O., Coosemans, W., De Leyn, P., Nafteux, P., Van Raemdonck, D., Van Cutsem, E., Hausterman, K., Lerut, T. (2003). Effects of preoperative chemoradiotherapy on postsurgical morbidity and mortality in cT3-4 +/- cM1lymph cancer of the oesophagus and gastro-oesophageal junction. Eur. J. Cardiothorac. Surg. 24: 179-186 [Abstract] [Full Text]  
• Ilson, D. H., Bains, M., Kelsen, D. P., O'Reilly, E., Karpeh, M., Coit, D., Rusch, V., Gonen, M., Wilson, K., Minsky, B. D. (2003). Phase I Trial of Escalating-Dose Irinotecan Given Weekly With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Cancer. JCO 21: 2926-2932 [Abstract] [Full Text]  
• Hagen, J. A., DeMeester, T. R. (2003). Staging of esophageal carcinoma. J. Thorac. Cardiovasc. Surg. 125: 988-991 [Full Text]  
• Jacob, R, Hawkes, N D, Dallimore, N, Butchart, E G, Thomas, G A O, Maughan, T S (2003). Squamous carcinoma in an oesophageal foregut cyst. Br. J. Radiol. 76: 343-346 [Abstract] [Full Text]  
• Kocher, H. M., Tekkis, P. P., Knisely, J. P.S., Burtness, B. A., Salem, R. R., van Lanschot, J. J. B., Tilanus, H. W., Obertop, H., Kitajima, M., Kitagawa, Y., Ozawa, S. (2003). Surgical Treatment of Esophageal Cancer. NEJM 348: 1177-1179 [Full Text]  
• Stilidi, I., Davydov, M., Bokhyan, V., Suleymanov, E. (2003). Subtotal esophagectomy with extended 2-field lymph node dissection for thoracic esophageal cancer. Eur. J. Cardiothorac. Surg. 23: 415-420 [Abstract] [Full Text]  
• Downey, R. J., Akhurst, T., Ilson, D., Ginsberg, R., Bains, M. S., Gonen, M., Koong, H., Gollub, M., Minsky, B. D., Zakowski, M., Turnbull, A., Larson, S. M., Rusch, V. (2003). Whole Body 18FDG-PET and the Response of Esophageal Cancer to Induction Therapy: Results of a Prospective Trial. JCO 21: 428-432 [Abstract] [Full Text]  
• Bailey, S. H., Bull, D. A., Harpole, D. H., Rentz, J. J., Neumayer, L. A., Pappas, T. N., Daley, J., Henderson, W. G., Krasnicka, B., Khuri, S. F. (2003). Outcomes after esophagectomy: a ten-year prospective cohort. Ann. Thorac. Surg. 75: 217-222 [Abstract] [Full Text]  
• Waters, J. S., Tait, D., Cunningham, D., Padhani, A. R., Hill, M. E., Falk, S., Lofts, F., Norman, A., Oates, J., Hill, A. (2002). A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus. Ann Oncol 13: 1763-1770 [Abstract] [Full Text]  
• De Vita, F., Di Martino, N., Orditura, M., Cosenza, A., Galizia, G., Del Genio, A., Catalano, G. (2002). Preoperative Chemoradiotherapy for Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus: A Phase II Study. Chest 122: 1302-1308 [Abstract] [Full Text]  
• Wren, S. M., Stijns, P., Srinivas, S. (2002). Positron Emission Tomography in the Initial Staging of Esophageal Cancer. Arch Surg 137: 1001-1006 [Abstract] [Full Text]  
• Bains, M. S., Stojadinovic, A., Minsky, B., Rusch, V., Turnbull, A., Korst, R., Ginsberg, R., Kelsen, D. P., Ilson, D. H. (2002). A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results. J. Thorac. Cardiovasc. Surg. 124: 270-277 [Abstract] [Full Text]  
• Doty, J. R., Salazar, J. D., Forastiere, A. A., Heath, E. I., Kleinberg, L., Heitmiller, R. F. (2002). Postesophagectomy morbidity, mortality, and length of hospital stay after preoperative chemoradiation therapy. Ann. Thorac. Surg. 74: 227-231 [Abstract] [Full Text]  
• Gupta, V. K., Park, J. O., Jaskowiak, N. T., Mauceri, H. J., Seetharam, S., Weichselbaum, R. R., Posner, M. C. (2002). Combined Gene Therapy and Ionizing Radiation Is a Novel Approach To Treat Human Esophageal Adenocarcinoma. Ann. Surg. Oncol. 9: 500-504 [Abstract] [Full Text]  
• Allum, W H, Griffin, S M, Watson, A, Colin-Jones, D (2002). Guidelines for the management of oesophageal and gastric cancer. Gut 50 : v1-v23 [Full Text]  
• Imdahl, A., Bognar, G., Schulte-Monting, J., Schoffel, U., Farthmann, E.H., Ihling, C. (2002). Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer. Eur. J. Cardiothorac. Surg. 21: 657-663 [Abstract] [Full Text]  
• Willett, C. G. (2002). Radiation Dose Escalation in Combined-Modality Therapy for Esophageal Cancer. JCO 20: 1151-1153 [Full Text]  
• Avendano, C. E., Flume, P. A., Silvestri, G. A., King, L. B., Reed, C. E. (2002). Pulmonary complications after esophagectomy. Ann. Thorac. Surg. 73: 922-926 [Abstract] [Full Text]  
• Flamen, P., Van Cutsem, E., Lerut, A., Cambier, J.-P., Haustermans, K., Bormans, G., De Leyn, P., Van Raemdonck, D., De Wever, W., Ectors, N., Maes, A., Mortelmans, L. (2002). Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13: 361-368 [Abstract] [Full Text]  
• Entwistle, J. W.C. III, Goldberg, M. (2002). Multimodality therapy for resectable cancer of the thoracic esophagus. Ann. Thorac. Surg. 73: 1009-1015 [Abstract] [Full Text]  
• Swisher, S. G., Wynn, P., Putnam, J. B., Mosheim, M. B., Correa, A. M., Komaki, R. R., Ajani, J. A., Smythe, W. R., Vaporciyan, A. A., Roth, J. A., Walsh, G. L. (2002). Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J. Thorac. Cardiovasc. Surg. 123: 175-183 [Abstract] [Full Text]  
• Symonds, R P (2001). Recent advances: Radiotherapy. BMJ 323: 1107-1110 [Full Text]  
• Dunne, B, Reynolds, J V, Mulligan, E, Kelly, A, Griffin, M (2001). A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy. J. Clin. Pathol. 54: 841-845 [Abstract] [Full Text]  
• Hagen, J. A., DeMeester, T. R. (2001). Esophageal adenocarcinoma. Ann. Thorac. Surg. 72: 1430-1432 [Full Text]  
• Kelly, S, Harris, K M, Berry, E, Hutton, J, Roderick, P, Cullingworth, J, Gathercole, L, Smith, M A (2001). A systematic review of the staging performance of endoscopic ultrasound in gastro-oesophageal carcinoma. Gut 49: 534-539 [Abstract] [Full Text]  
• Aquino, S. L., Lee, K. S., Kim, S. H. (2001). Invited Commentary Authors' Response. RadioGraphics 21: 1138-1140 [Full Text]  
• Lowy, A. M., Feig, B. W., Janjan, N., Rich, T. A., Pisters, P. W. T., Ajani, J. A., Mansfield, P. F. (2001). A Pilot Study of Preoperative Chemoradiotherapy for Resectable Gastric Cancer. Ann. Surg. Oncol. 8: 519-524 [Abstract] [Full Text]  
• Lew, J. I., Gooding, W. E., Ribeiro, U. Jr, Safatle-Ribeiro, A. V., Posner, M. C. (2001). Long-term Survival Following Induction Chemoradiotherapy and Esophagectomy for Esophageal Carcinoma. Arch Surg 136: 737-742 [Abstract] [Full Text]